Breast Cancer
Conditions
Brief summary
This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult patients, \>/=18 years of age * Previously untreated metastatic breast cancer * Scheduled to start 1st line chemotherapeutic treatment * ECOG performance status 0-1
Exclusion criteria
* Any conditions included in contraindication list for Avastin * Prior chemotherapy for metastatic breast cancer * Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic malignancy completed \<6 months prior to treatment start
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between the time from start of chemotherapy to the start of Avastin treatment with progression-free survival | 60 months |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 60 months |
| Safety: Incidence of adverse events | 60 months |
Countries
Romania